Skip to content

Trial Summary

This study is designed to estimate the effectiveness of nivolumab when given to participants after removing their cancer with surgery, over a 5-year follow-up, in real-world conditions in Australia.

Acronym:

CA209-7CK

ACTRN/NCT /ethics:

NCT04146324

Scientific title:

A prospective, observational study in patients receiving adjuvant nivolumab therapy for resected melanoma in Australia

Sponsor / Cooperative group:

Bristol-Myers Squibb

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeEarly detection, diagnosis, prognosis
PhaseAll phases
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2019-10-31
Anticipated End Date2025-07-09

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6140
Principal InvestigatorDr Rachel Roberts-Thomson
Recruitment StatusRecruiting